Quarterly report pursuant to Section 13 or 15(d)

Research and License Agreements (Details Narrative)

v3.20.2
Research and License Agreements (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2020
May 31, 2020
Mar. 31, 2019
Dec. 31, 2018
Aug. 31, 2018
Jun. 30, 2018
Jun. 30, 2020
Jun. 30, 2019
Mar. 31, 2018
Research and development             $ 597,345 $ 147,641  
Product Sales [Member]                  
Licensed product sales, revenue             420,000 950,000  
University of Louisville Research Foundation [Member] | Minimum [Member] | Royalties and Non-Royalty Sublicensee Income [Member]                  
Shortfall payments             5,000    
University of Louisville Research Foundation [Member] | Maximum [Member] | Royalties and Non-Royalty Sublicensee Income [Member]                  
Shortfall payments             50,000    
Sekisui Diagnostics, LLC [Member] | May 2016 [Member]                  
Financing payments for product development                 $ 7,200,000
License and Sponsored Research Agreements [Member]                  
Research and development             2,000 33,000  
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]                  
Payment of convertible promissory note         $ 50,000 $ 50,000      
Reimbursement of research expenses         348,000 348,000      
Reimbursement patent cost         $ 200,000 $ 200,000      
Agreement term payment, description         In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter) In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter)      
Licensed product sales, revenue         $ 500,000,000 $ 500,000,000      
Milestone payment for marketing expenses         500,000 500,000      
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]                  
Regulatory marketing approval, expenses         500,000 500,000      
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member]                  
Milestone payment         100,000 100,000      
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member]                  
Milestone payment         200,000 200,000      
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member]                  
Milestone payment         350,000 350,000      
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                  
Milestone payment         100,000 100,000      
Shortfall payments         10,000 10,000      
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                  
Milestone payment         5,000,000 5,000,000      
Shortfall payments         $ 50,000 $ 50,000      
License Agreement [Member] | University of Louisville Research Foundation [Member]                  
Upfront license fee             $ 20,000    
ULRF license agreement description             In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $50,000 for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales.    
License Agreement [Member] | University of Louisville Research Foundation [Member] | Subsequent Event [Member]                  
Research and development $ 250,000                
License Agreement [Member] | Advanced Cancer Therapeutics [Member]                  
Proceeds from convertible promissory note       $ 25,000          
Agreement description       Royalties, on net sales associated with the commercialization of ACT-GRO-777/AS1411, of 2% (only if patent-covered and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000), until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $100,000 for the Company raising a cumulative total of $2,000,000 in new equity financing after the date of the ACT license agreement, $100,000 upon any first AS1411-based licensed product receiving the CE Mark or similar FDA status, and $500,000 upon cumulative worldwide AS1411-based licensed product net sales reaching $3,000,000          
Milestone payment   $ 100,000              
Cumulative amount   $ 2,000,000              
Sponsored Research and License Agreement [Member]                  
Sponsored research expense             $ 139,000 $ 20,000  
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]                  
Research and development     $ 693,000